Stryker Corporation operates as a medical technology company.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$273.48|
|52 Week High||US$196.09|
|52 Week Low||US$281.16|
|1 Month Change||0.022%|
|3 Month Change||5.01%|
|1 Year Change||31.96%|
|3 Year Change||53.08%|
|5 Year Change||134.85%|
|Change since IPO||17,579.52%|
Recent News & Updates
|SYK||US Medical Equipment||US Market|
Return vs Industry: SYK matched the US Medical Equipment industry which returned 32.6% over the past year.
Return vs Market: SYK matched the US Market which returned 32.8% over the past year.
Stable Share Price: SYK is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: SYK's weekly volatility (3%) has been stable over the past year.
About the Company
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries.
Stryker Fundamentals Summary
|SYK fundamental statistics|
Is SYK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|SYK income statement (TTM)|
|Cost of Revenue||US$5.59b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Oct 28, 2021
|Earnings per share (EPS)||5.52|
|Net Profit Margin||12.82%|
How did SYK perform over the long term?See historical performance and comparison
0.9%Current Dividend Yield
Does SYK pay a reliable dividends?See SYK dividend history and benchmarks
|Stryker dividend dates|
|Ex Dividend Date||Sep 29 2021|
|Dividend Pay Date||Oct 29 2021|
|Days until Ex dividend||0 days|
|Days until Dividend pay date||30 days|
Does SYK pay a reliable dividends?See SYK dividend history and benchmarks
Is Stryker undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SYK ($273.48) is trading above our estimate of fair value ($238.06)
Significantly Below Fair Value: SYK is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SYK is good value based on its PE Ratio (49.5x) compared to the US Medical Equipment industry average (51.4x).
PE vs Market: SYK is poor value based on its PE Ratio (49.5x) compared to the US market (18.1x).
Price to Earnings Growth Ratio
PEG Ratio: SYK is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: SYK is overvalued based on its PB Ratio (7.5x) compared to the US Medical Equipment industry average (4.7x).
How is Stryker forecast to perform in the next 1 to 3 years based on estimates from 28 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SYK's forecast earnings growth (23% per year) is above the savings rate (2%).
Earnings vs Market: SYK's earnings (23% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SYK's revenue (6.6% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: SYK's revenue (6.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SYK's Return on Equity is forecast to be high in 3 years time (23.2%)
How has Stryker performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SYK has a large one-off loss of $904.0M impacting its June 30 2021 financial results.
Growing Profit Margin: SYK's current net profit margins (12.8%) are higher than last year (11.4%).
Past Earnings Growth Analysis
Earnings Trend: SYK's earnings have grown by 6% per year over the past 5 years.
Accelerating Growth: SYK's earnings growth over the past year (30.1%) exceeds its 5-year average (6% per year).
Earnings vs Industry: SYK earnings growth over the past year (30.1%) underperformed the Medical Equipment industry 40.5%.
Return on Equity
High ROE: SYK's Return on Equity (15.1%) is considered low.
How is Stryker's financial position?
Financial Position Analysis
Short Term Liabilities: SYK's short term assets ($9.0B) exceed its short term liabilities ($4.3B).
Long Term Liabilities: SYK's short term assets ($9.0B) do not cover its long term liabilities ($15.6B).
Debt to Equity History and Analysis
Debt Level: SYK's debt to equity ratio (92.2%) is considered high.
Reducing Debt: SYK's debt to equity ratio has increased from 83.9% to 92.2% over the past 5 years.
Debt Coverage: SYK's debt is well covered by operating cash flow (26.7%).
Interest Coverage: SYK's interest payments on its debt are well covered by EBIT (10.7x coverage).
What is Stryker current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SYK's dividend (0.92%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.3%).
High Dividend: SYK's dividend (0.92%) is low compared to the top 25% of dividend payers in the US market (3.57%).
Stability and Growth of Payments
Stable Dividend: SYK's dividends per share have been stable in the past 10 years.
Growing Dividend: SYK's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (44.5%), SYK's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SYK's dividends in 3 years are forecast to be well covered by earnings (25.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Lobo (56 yo)
Mr. Kevin A. Lobo has been the Chief Executive Officer of Stryker Corporation since October 1, 2012. He serves as Chairman of the Board at The Advanced Medical Technology Association (AdvaMed). He serves a...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD13.32M) is about average for companies of similar size in the US market ($USD11.29M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Experienced Management: SYK's management team is considered experienced (3.3 years average tenure).
Experienced Board: SYK's board of directors are considered experienced (4.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SYK insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Stryker Corporation's employee growth, exchange listings and data sources
- Name: Stryker Corporation
- Ticker: SYK
- Exchange: NYSE
- Founded: 1941
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$103.128b
- Shares outstanding: 377.10m
- Website: https://www.stryker.com
Number of Employees
- Stryker Corporation
- 2825 Airview Boulevard
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 22:54|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.